| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | F13A1 |
| Uniprot No | P00488 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 39-732aa |
| 氨基酸序列 | GVNLQEFLNVTSVHLFKERWDTNKVDHHTDKYENNKLIVRRGQSFYVQIDFSRPYDPRRDLFRVEYVIGRYPQENKGTYIPVPIVSELQSGKWGAKIVMREDRSVRLSIQSSPKCIVGKFRMYVAVWTPYGVLRTSRNPETDTYILFNPWCEDDAVYLDNEKEREEYVLNDIGVIFYGEVNDIKTRSWSYGQFEDGILDTCLYVMDRAQMDLSGRGNPIKVSRVGSAMVNAKDDEGVLVGSWDNIYAYGVPPSAWTGSVDILLEYRSSENPVRYGQCWVFAGVFNTFLRCLGIPARIVTNYFSAHDNDANLQMDIFLEEDGNVNSKLTKDSVWNYHCWNEAWMTRPDLPVGFGGWQAVDSTPQENSDGMYRCGPASVQAIKHGHVCFQFDAPFVFAEVNSDLIYITAKKDGTHVVENVDATHIGKLIVTKQIGGDGMMDITDTYKFQEGQEEERLALETALMYGAKKPLNTEGVMKSRSNVDMDFEVENAVLGKDFKLSITFRNNSHNRYTITAYLSANITFYTGVPKAEFKKETFDVTLEPLSFKKEAVLIQAGEYMGQLLEQASLHFFVTARINETRDVLAKQKSTVLTIPEIIIKVRGTQVVGSDMTVTVQFTNPLKETLRNVWVHLDGPGVTRPMKKMFREIRPNSTVQWEEVCRPWVSGHRKLIASMSSDSLRHVYGELDVQIQRRPSM |
| 预测分子量 | 81.2kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为模拟生成的关于F13A1重组蛋白的参考文献示例(非真实文献，仅供格式参考)：
1. **"Recombinant human coagulation factor XIII A subunit: expression and functional characterization"**
*Smith J, et al.*
摘要：研究通过哺乳动物细胞系统表达重组人F13A1蛋白，验证其酶活性及在体外凝血模型中的功能，证明其与天然蛋白具有相似特性。
2. **"Production of biologically active F13A1 in E. coli: challenges and solutions"**
*Chen L, Wang H.*
摘要：报道在大肠杆菌中表达重组F13A1的优化策略，包括密码子优化和包涵体复性方法，成功获得具有转谷氨酰胺酶活性的可溶性蛋白。
3. **"Therapeutic potential of recombinant F13A1 in wound healing: a preclinical study"**
*Kim S, et al.*
摘要：动物实验表明，局部应用重组F13A1可加速伤口闭合，机制涉及增强纤维蛋白交联和促进成纤维细胞迁移。
4. **"Structural analysis of recombinant FXIII-A2 subunit complex using cryo-EM"**
*Gupta R, et al.*
摘要：利用冷冻电镜解析重组表达的FXIII-A2二聚体三维结构，揭示其催化中心构象变化与酶激活的关系。
---
**说明**：以上文献为模拟生成，实际参考文献建议通过PubMed、Web of Science等数据库搜索关键词(例如："recombinant F13A1"、"FXIII-A subunit expression")，并优先选择近5年高被引论文。真实文献可能涉及以下方向：重组表达系统优化、止血机制研究、结构生物学分析或临床应用开发。
**Background of F13A1 Recombinant Protein**
F13A1. also known as coagulation factor XIII A chain, is a critical enzyme in the blood coagulation cascade. It functions as a transglutaminase that stabilizes blood clots by cross-linking fibrin polymers, enhancing clot stability and resistance to fibrinolysis. The native factor XIII is a heterotetramer composed of two catalytic A subunits (F13A1) and two carrier B subunits (F13B). F13A1 is synthesized in cells such as megakaryocytes, monocytes, and macrophages, while F13B is produced in the liver.
Recombinant F13A1 protein is generated using biotechnological methods, typically through expression in mammalian cell systems (e.g., CHO cells) to ensure proper post-translational modifications and functional activity. The recombinant form retains the enzymatic properties of the native protein, existing as a zymogen that requires thrombin-mediated cleavage (in the presence of calcium ions) for activation.
Clinically, recombinant F13A1 has therapeutic potential in managing congenital factor XIII deficiency, a rare bleeding disorder characterized by impaired clot stabilization. It is also investigated for applications in trauma, surgical settings, and wound healing due to its role in tissue repair. Additionally, research explores its utility in bioengineering, such as fibrin-based scaffolds for regenerative medicine.
Studies highlight its safety and efficacy in restoring hemostasis, with ongoing efforts to optimize production yields and explore novel indications. The development of recombinant F13A1 underscores advancements in recombinant protein technology to address unmet medical needs in hematology and beyond.
×
